Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04749394 | A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy | unknown | Phase 2 | 42 | Chinese Academy of Medical SciencesOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05332574 | A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Aug 5, 2022 |
| NCT05117658 | Study of HA121-28 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 2 | 83 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05255406 | Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05485350 | Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 32 | Peking University Third HospitalOTHER | 0 | Aug 3, 2022 | clinicaltrials |
| NCT05483543 | Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy | unknown | Phase 2 | 44 | Fudan UniversityOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05482087 | A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC | unknown | Phase 2 | 190 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05477615 | Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases | unknown | Phase 2 | 28 | Jin Hyoung KangOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05068024 | A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer(FWD1509) | unknown | Phase 1 / Phase 2 | 30 | Forward Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05458726 | Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC | unknown | Phase 2 | 80 | Peking Union Medical CollegeOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05472467 | Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer(IMCORT-2) | unknown | Phase 2 | 35 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05468294 | F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer(Nivokin) | unknown | Phase 1 / Phase 2 | 3 | Philogen S.p.A.INDUSTRY | 1 | Jul 21, 2022 | clinicaltrials |
| NCT05460481 | Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors | unknown | Phase 2 | 29 | Hunan Cancer HospitalOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05460195 | Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation | unknown | Phase 2 | 42 | Shanghai Chest HospitalOTHER | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04459611 | Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）(neoSCORE) | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05451056 | An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib(breakthrough) | unknown | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05448781 | Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC | unknown | Phase 2 | 38 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Jul 7, 2022 | clinicaltrials |
| NCT05435274 | Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 380 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 28, 2022 | clinicaltrials |
| NCT05414630 | A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer | unknown | Phase 2 | 30 | Anhui Provincial Cancer HospitalOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT05394233 | Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05387044 | SBRT for Oligoprogressive NSCLC After First Line Treatment With Immune Checkpoint Inhibitors | unknown | Phase 2 | 28 | Zhejiang Cancer HospitalOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05085054 | Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT) | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 20, 2022 | clinicaltrials |
| NCT05380271 | Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC | unknown | Phase 2 | 60 | Gang WuOTHER | 0 | May 18, 2022 | clinicaltrials |
| NCT05354700 | A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | May 4, 2022 | clinicaltrials |
| NCT05360979 | A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC | unknown | Phase 2 | 42 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | May 4, 2022 | clinicaltrials |
| NCT02562963 | Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 120 | Minghui ZhangOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04878107 | SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy(SABRE) | unknown | Phase 2 | 88 | Wuhan UniversityOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT05162196 | The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 57 | Wuhan UniversityOTHER | 0 | May 2, 2022 | clinicaltrials |
| NCT05351320 | WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC | unknown | Phase 2 | 40 | Jinming YuOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05329298 | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT01441349 | Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer | unknown | Phase 2 | 192 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT01470716 | Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations | unknown | Phase 2 | 26 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03612154 | Study of Lorlatinib in ROS1 Rearranged NSCLC | unknown | Phase 2 | 35 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03808480 | Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% | unknown | Phase 2 | 22 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04040361 | Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) | unknown | Phase 2 | 24 | Masahiro TsuboiOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05306847 | Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer | unknown | Phase 2 | 93 | Peking Union Medical College HospitalOTHER | 0 | Apr 1, 2022 | clinicaltrials |
| NCT05299255 | Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2022 | clinicaltrials |
| NCT05236608 | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC(ADIVO Lung) | unknown | Phase 1 / Phase 2 | 53 | National University Hospital, SingaporeOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT05287386 | A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05284994 | TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 160 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT04690686 | Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 24 | Immunicom IncINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05267392 | Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy(IDEAR) | unknown | Phase 1 / Phase 2 | 30 | Instituto Portugues de Oncologia, Francisco Gentil, PortoOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04956146 | Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | unknown | Phase 2 | 46 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05252091 | An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC | unknown | Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 23, 2022 | clinicaltrials |
| NCT05245994 | An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese | unknown | Phase 2 | 60 | Li Zhang, MDOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03801200 | Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC | unknown | Phase 2 | 90 | Hubei Cancer HospitalOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02446704 | Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy | unknown | Phase 1 / Phase 2 | 66 | Zofia PiotrowskaOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT05207904 | Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases | unknown | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Aug 16, 2022source: clinicaltrials